Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy

Cancer

Volumn 119, Issue 18, 2013, Pages 3287-3294

  Jackson, William ^a   Hamstra, Daniel A ^a   Johnson, Skyler ^a   Zhou, Jessica ^a   Foster, Benjamin ^a   Foster, Corey ^a   Li, Darren ^a   Song, Yeohan ^a   Palapattu, Ganesh S ^b   Kunju, Lakshmi P ^a   Mehra, Rohit ^a   Feng, Felix Y ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Gleason pattern; outcomes; prognosis; prostate cancer; salvage radiation therapy

Indexed keywords

ANTIANDROGEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BIOCHEMISTRY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; DISTANT METASTASIS; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; SALVAGE THERAPY; TERTIARY HEALTH CARE; TREATMENT FAILURE; TREATMENT RESPONSE;

GLEASON PATTERN; OUTCOMES; PROGNOSIS; PROSTATE CANCER; SALVAGE RADIATION THERAPY;

AGED; ANDROGENS; BIOPSY, NEEDLE; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS;

EID: 84883597067     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28215     Document Type: Article

References (26)

1. Roehl KA, Han M, Ramos CG, Antenor JAV, Catalona WJ,. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004; 172: 910-914. (Pubitemid 39096421)
2. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC,. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001; 28: 555-565. (Pubitemid 32916759)
3. Cotter SE, Chen MH, Moul JW, et al. Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer. 2011; 117: 3925-3932.
4. Katz MS, Zelefsky MJ, Venkatraman ES, Fuks Z, Hummer A, Leibel SA,. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol. 2003; 21: 483-489. (Pubitemid 46606478)
5. Goenka A, Magsanoc JM, Pei X, et al. Long-term outcomes after high-dose postprostatectomy salvage radiation treatment. Int J Radiat Oncol Biol Phys. 2012; 84: 112-118.
6. Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008; 299: 2760-2769. (Pubitemid 351846851)
7. Stephenson AJ, Scardino PT, Kattan MW,. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007; 25: 4153-4153.
8. Hashine K, Yuasa A, Shinomori K, Shirato A, Ninomiya I, Teramoto N,. Tertiary Gleason pattern 5 and oncological outcomes after radical prostatectomy. Jpn J Clin Oncol. 2011; 41: 571-576.
9. Trock BJ, Guo CC, Gonzalgo ML, Magheli A, Loeb S, Epstein JI,. Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system. J Urol. 2009; 182: 1364-1370.
10. Stock RG, Cesaretti JA, Hall SJ, Stone NN,. Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy. BJU Int. 2009; 104: 1631-1636.
11. Sabolch A, Feng FY, Daignault-Newton S, et al. Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation. Int J Radiat Oncol Biol Phys. 2011; 81: e351-e360.
12. Vis AN, Roemeling S, Kranse R, Schroder FH, van der Kwast TH,. Should we replace the Gleason score with the amount of high-grade prostate cancer? Eur Urol. 2007; 51: 931-939. (Pubitemid 46281411)
13. Nanda A, Chen MH, Renshaw AA, D'Amico AV,. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials. Int J Radiat Oncol Biol Phys. 2009; 74: 1419-1423.
14. Cheng L, Koch MO, Juliar BE, et al. The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy. J Clin Oncol. 2005; 23: 2911-2917. (Pubitemid 46224109)
15. Spiotto MT, Hancock SL, King CR,. Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Oncol Biol Phys. 2007; 69: 54-61. (Pubitemid 47247505)
16. Shipley WU, Hunt D, Lukka HR, et al. Initial report of RTOG 9601, a phase III trial in prostate cancer: Effect of anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) on freedom from progression and incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3,N0 disease and elevated PSA levels. J Clin Oncol. 2011; 29: 1.
17. Cooperberg MR, Hilton JF, Carroll PR,. The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer. 2011; 117: 5039-5046.
18. Fine JP, Gray RJ,. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94: 496-509.
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383. (Pubitemid 17055592)
20. D'Ambrosio DJ, Hanlon AL, Al-Saleem T, et al. The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2007; 67: 1082-1087.
21. Shilkrut M, McLaughlin W, Merrick GS, et al. Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiotherapy [published online ahead of print May 9, 2013 ]. Int J Radiat Oncol Biol Phys. doi: 10.1016/j.ijrobp.2013.03.028.
22. Buyyounouski MK, Hanlon AL, Horwitz EM, Pollack A,. Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. Int J Radiat Oncol Biol Phys. 2008; 70: 59-66. (Pubitemid 350251025)
23. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005; 294: 433-439. (Pubitemid 41124175)
24. Johnson S, Jackson W, Li D, et al. The interval to biochemical failure is prognostic for metastasis, prostate cancer-specific mortality, and overall mortality after salvage radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2013; 86: 554-561.
25. Benaim EA, Pace CM, Roehrborn CG,. Gleason score predicts androgen independent progression after androgen deprivation therapy. Eur Urol. 2002; 42: 12-17. (Pubitemid 35339640)
26. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL,. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005; 29: 1228-1242. (Pubitemid 41232997)